I think they are looking for a new angle for a story on Brockman. I'd say it could now be on the conflict of interest in the board or the new CEO having a say on the current Wah Nam offer in light of the latest at Sirius.
Some kind of valuation needs to be attributed in the current offer for BRM's other licences. Especially if they are going to be as good as Ophthalmia!
Not sure exactly...guess I'll wait and see.
BRM Price at posting:
$2.11 Sentiment: Buy Disclosure: Held